Newsroom

- OnQuality will present preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment...

- OnQuality will present an update on its NOVA-II Phase 2 clinical trial investigating OQL011, a proprietary ointment designed to treat...

Full Title: OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for New Cancer Therapy-Associated Diarrhea...

Therapy Induced Skin Toxicity that Met Expectations - Part 1 of the Phase 2 NOVA-II clinical trial evaluating OQL011 met the company's...

- Top-line readout of clinical study results anticipated by the end of 2021 SEATTLE, Sept. 7, 2021 /PRNewswire/ -- OnQuality...

SEATTLE, June 9, 2021 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted cancer supportive care company developing...

OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011 at the 2021 ASCO and MASCC/ISOO Annual Meetings SEATTLE, May 19,...

SEATTLE and SHANGHAI—March 31, 2021. OnQuality Pharmaceuticals LLC ("OnQuality"), a targeted cancer supportive care company developing me...

Seattle, WA—August 14, 2020. OnQuality Pharmaceuticals (USA) LLC, dedicated to the discovery and development of therapies to improve qua...

Shanghai, China—Oct. 28th, 2019. OnQuality Pharmaceuticals Ltd., a start-up pharmaceutical company focusing on mitigating on-target toxic...